Loxo Oncology, Inc. (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the company’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $89.02, for a total transaction of $1,335,300.00. Following the transaction, the chief executive officer now owns 196,207 shares in the company, valued at $17,466,347.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Loxo Oncology, Inc. (NASDAQ:LOXO) traded up 0.59% during mid-day trading on Thursday, hitting $90.76. 187,249 shares of the stock traded hands. The stock has a 50 day moving average price of $77.03 and a 200 day moving average price of $61.97. The firm’s market cap is $2.71 billion. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $91.18.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). During the same period in the prior year, the business earned ($0.77) EPS. On average, analysts expect that Loxo Oncology, Inc. will post ($4.54) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) CEO Joshua H. Bilenker Sells 15,000 Shares” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/21/loxo-oncology-inc-loxo-ceo-joshua-h-bilenker-sells-15000-shares.html.

Several research analysts have weighed in on LOXO shares. Citigroup Inc. upgraded shares of Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Monday, June 5th. Stifel Nicolaus increased their price target on shares of Loxo Oncology from $52.00 to $71.00 and gave the company a “buy” rating in a research report on Monday, June 5th. Cowen and Company reiterated an “outperform” rating on shares of Loxo Oncology in a research report on Monday, June 5th. BTIG Research reiterated a “buy” rating and issued a $75.00 price target on shares of Loxo Oncology in a research report on Tuesday, June 6th. Finally, Zacks Investment Research upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, June 8th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Loxo Oncology currently has an average rating of “Buy” and an average price target of $70.73.

Several institutional investors have recently added to or reduced their stakes in LOXO. Teachers Advisors LLC increased its position in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 905 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after acquiring an additional 6,632 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after acquiring an additional 3,875 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Loxo Oncology by 41.8% in the first quarter. Bank of New York Mellon Corp now owns 102,442 shares of the biopharmaceutical company’s stock worth $4,310,000 after acquiring an additional 30,210 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Loxo Oncology by 53.5% in the first quarter. Swiss National Bank now owns 28,700 shares of the biopharmaceutical company’s stock worth $1,208,000 after acquiring an additional 10,000 shares in the last quarter.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.